Dimension falls on liver toxicity concerns

Dimension Therapeutics Inc. (NASDAQ:DMTX) fell $2.30 (54%) to $1.95 after it said it would wait for advice before advancing gene therapy candidate DTX101 to the third cohort of a Phase I/II trial to treat hemophilia B. The company said it had observed elevated liver enzyme measurements in the study.

Of six patients treated with DTX101 in the dose-escalation trial’s first two cohorts, five experienced elevated aminotransferase (ALT) levels, including one with a grade 4 adverse event in the higher-dose cohort. The company said it reported the findings to a DSMC and FDA, and will wait for a response before beginning dosing of the planned third cohort. ...